• Citer

A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies.

par Heath, Elisabeth I;Lorusso, Patricia;Ramalingam, Suresh S;Awada, Ahmad ;Egorin, Merrill J;Besse-Hammer, Tatiana;Cardoso, Fatima ;Valdivieso, Manuel;Has, Teresa;Alland, Leila;Zhou, Xiaofei;Belani, Chandra P
Référence Investigational new drugs, 29, 6, page (1426-1431)
Publication Publié, 2011-12

Article révisé par les pairs

• Détails
• Contenu

Résumé :

BMS-275183 is an oral C-4 methyl carbonate analogue of paclitaxel that has the same mechanism of action, stabilization of tubulin polymerization. The present study was designed to: (i) assess the safety and tolerability of BMS-275183, and (ii) determine a suitable Phase II dose of BMS-275183 when given on a continuous daily schedule to patients with advanced solid tumor(s).